

**PHG Needs Assessment Calculator****Norway****Neural Tube Defects**

Welcome to the PHG Health Needs Assessment Calculator for Neural Tube Defects. The contents of this file are listed below.

<b>Full name of the sheet</b>	<b>Short name</b>
Country demographic, maternal health and socioeconomic indicators	Demography
Country health service data	HealthServices
NTD Epidemiology 1.1: Country epidemiology	NTD-E1.1
NTD Epidemiology 1.2: International comparison	NTD-E1.2
NTD Epidemiology 2.1: Data on affected pregnancies: Research studies	NTD-E2.1
NTD Epidemiology 2.2: Data on affected pregnancies: Surveillance	NTD-E2.2
NTD Epidemiology 2.3: Data on affected pregnancies: Other sources	NTD-E2.3
NTD Epidemiology 2.4: Summary of affected pregnancies	NTD-E2.4
NTD Epidemiology 2.5: Sub-population variation in affected pregnancies	NTD-E2.5
NTD Epidemiology 3.1: Mortality data: Research studies	NTD-E3.1
NTD Epidemiology 3.2: Mortality data: Vital registration data	NTD-E3.2
NTD Epidemiology 3.3: Mortality data: Other sources	NTD-E3.3
NTD Epidemiology 3.4: Summary mortality estimates	NTD-E3.4
NTD Epidemiology 3.5: Sub-population variation in mortality	NTD-E3.5
NTD Epidemiology 4.1: Population prevalence: Research studies	NTD-E4.1
NTD Epidemiology 4.2: Population prevalence: Other sources	NTD-E4.2
NTD Epidemiology 4.3: Summary of population prevalence	NTD-E4.3
NTD Epidemiology 4.4: Sub-population prevalence variation	NTD-E4.4
NTD Interventions 1: Effect of folic acid fortification	NTD-Interv1
NTD Interventions 2: Effect of folic acid supplementation	NTD-Interv2
NTD Interventions 3: Effects of prenatal screening and pregnancy termination	NTD-Interv3
NTD Interventions 4: Combined effects of folic acid interventions and prenatal screening	NTD-Interv4
NTD Needs Assessment Calculator 1: Quantitative baseline	NTD-NA1
NTD Needs Assessment Calculator 3: Quantitative assessment of interventions	NTD-NA3
NTD Needs Assessment Appendix: Regression estimating effect of folate fortification	NTD-Appx

(There is no sheet NTD-NA2.)

**Norway****Shared Data****Demographic, maternal health and socio-economic indicators**

**Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.**

**By default, the Toolkit contains information at the national level.**

**If you would like to use a different population, then replace country information with that of your specific population of interest.**

Number of persons by age-group and sex Age group	Estimates			Your estimates			Chosen estimates		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4 years	155882	148046	303928			0			0
5-9 years	152416	146057	298473			0			0
10-14 years	161955	153369	315324			0			0
15-19 years	165748	156284	322032			0			0
20-24 years	155602	149912	305514			0			0
25-29 years	155740	151363	307103			0			0
30-34 years	162005	156153	318158			0			0
35-39 years	183832	175471	359303			0			0
40-44 years	188180	177839	366019			0			0
45-49 years	171934	162742	334676			0			0
50-54 years	162279	156320	318599			0			0
55-59 years	149665	145550	295215			0			0
60-64 years	146836	144346	291182			0			0
65+ years	314678	407995	722673			0			0
Total	0	0	4858199	0	0	0	0	0	0
Female population aged 15-44 years		0			-			-	
Data year	2010 reported in 2011								
Source, Year	UN 2011								

**Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.**

Ethnic group	Number	% population

<b>Fertility and mortality</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Crude birth rate: live births (LB) / year / 1000 population	12	Unicef, 2007				
Still birth rate (SB): Still births (SB) / year / 1000 total births	2	WHO, 2009				
Total births in 1000s (LB+SB) per year	56	Unicef, 2007				
Infant mortality rate: infant deaths / 1000 LB / year	3	UNICEF				
Under-5 mortality rate: U5 deaths / 1000 LB / year	3	(2011), 2010				
Percentage births in women >35 years		(2011), 2010				
Life expectancy at birth (yrs)	81	WHO, 2009				
% of marriages consanguineous						

<b>Maternal health</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Prenatal visits – at least 1 visit (%)						
Prenatal visits – at least 4 visits (%)						
Births attended by skilled health personnel (%)						
Contraception prevalence rate (%)	88.4	WHO, 2005				
Unmet need for family planning (%)						
Total fertility rate	1.9	WHO, 2009				
% home births						
% births at health care services						
<b>Newborn health</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Number of neonatal examinations by SBA / trained staff						
% neonatal examinations by SBA/ trained staff						

<b>Socio-economic indicators</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Gross national income per capita (PPP int. \$)	59250	WHO, 2008				
% population living on < US\$1 per day						
Birth registration coverage (%)	>90	WHO, 2008				
Death registration coverage (%)	90-100	WHO, 2009				

LB = live births

PPP = purchasing power parity

SBA = skilled birth attendant

**Norway**  
**Shared Data**  
**Health Services Data**

**Please read first!** If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

**By default, the Toolkit contains information at the national level.**

**If you would like to use a different population, then replace country information with that of your specific population of interest.**

<b>Health Expenditure</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Per capita total expenditure on health (PPP int. \$)	5395	WHO, 2009				
Total expenditure on health as percentage of GDP	9.7	WHO, 2009				
Per capita government expenditure on health (PPP int. \$)	4237	WHO, 2009				
External resources for health as percentage of total expenditure on health	0	WHO, 2009				
General government expenditure on health as percentage of total expenditure on health	78.6	WHO, 2009				
Out-of-pocket expenditure as percentage of private expenditure on health	98.8	WHO, 2009				
Private expenditure on health as percentage of total expenditure on health	15.6	WHO, 2009				
General government expenditure on health as percentage of total government expenditure	16.7	WHO, 2009				

<b>Health Workforce</b>	<b>Estimate</b>	<b>Source, Year</b>	<b>Your estimate</b>	<b>Source, Year</b>	<b>Chosen estimate</b>	<b>Source, Year</b>
Number of nursing and midwifery personnel	69176	WHO, 2008				
Nursing and midwifery personnel density (per 10,000 population)	147.6	WHO, 2008				
Number of physicians	19104	WHO, 2008				
Physician density (per 10,000 population)	40.76	WHO, 2008				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						
Number of paediatric neurosurgeons						
Number of clinical geneticists						
Number of genetic counsellors						
Number of community health workers						
Number of skilled birth attendants (SBA)						
Density of SBA						
Number of lab staff providing cytogenetic testing						

Number of lab staff providing molecular genetics						
Number of lab staff providing biochemical tests for genetics						
Number of skilled health attendants						

Infrastructure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of maternity units						
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facilities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity

GDP = gross domestic product

SBA = skilled birth attendant

CD = congenital disorders

## Norway

## Neural Tube Defects

## NTD Epidemiology 1.1: Country epidemiology

Epidemiological indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
<b>Year of estimate</b>						
<b>Prevalence at birth and by age-group (/1000)</b>						
Live birth prevalence (LB)			0.23			
Stillbirth prevalence (SB)			0.02			
Total birth prevalence (LB+SB)			0.25			
All age groups			0.08			
<1 year olds			0.19			
1-4 year olds			0.19			
5-14 year olds			0.14			
15-44 year olds			0.11			
45+ year olds			0.00			
<b>Number of cases by age group</b>						
Annual live births			12			
All age groups			355			
<1 year olds			11			
1-4 year olds			43			
5-14 year olds			88			
15-44 year olds			212			
45+ year olds			0			
<b>No. of cases by level of impairment</b>						
No or minor disability			0			
Moderate disability			0			
Severe disability*			355			
<b>Mortality and morbidity</b>						
Mean life expectancy (yrs)			56.0			
No. deaths < 1yr			1			
No. deaths 1-4 yrs			0			
No. deaths < 5 yrs			2			
Infant mortality / 1000 LB			0.03			
Under-5 mortality / 1000 LB			0.03			
Years of life lost			1,295			

LB = live births; SB = stillbirths \* Severe disability is defined as: wheelchair dependence, needing help with transfers, continence care and daily living, mostly low IQ, kyphosis, pressure sores, epilepsy and visual defects (a few blind) (Oakeshott and Hunt 2003)

## Norway

## Neural Tube Defects

## NTD Epidemiology 1.2: International comparison

	Your chosen estimates	Comparison		
Epidemiological indicator		Country	Region	World
Prevalence at birth and by age-group (/1000 people)		(Europe, Western)		
Live birth prevalence (LB)		0.23	0.22	1.70
Stillbirth prevalence (SB)		0.02	0.03	0.56
Total birth prevalence (LB+SB)		0.25	0.25	2.27
All age groups		0.08		
<1 year olds		0.19		
1-4 year olds		0.19		
5-14 year olds		0.14		
15-44 year olds		0.11		
45+ year olds		0.00		
Number of cases by age-group				
Annual live births		12	913	226,432
All age groups		355	21338	564261
<1 year olds		11		
1-4 year olds		43	1671	126519
5-14 year olds		88	4637	243746
15-44 year olds		212	15006	193592
45+ year olds		0	24	404
No. cases by level of impairment				
No or minor disability		0		
Moderate disability		0		
Severe disability*		355	21338	564261
Mortality and morbidity				
Mean life expectancy (yrs)		56.0	56.0	7.8
No. deaths < 1yr		1	144	182,680
No. deaths 1-4 yrs		0	26	6,250
No. deaths < 5 yrs		2	170	188,931
Infant mortality / 1000 LB		0.03		
Under-5 mortality / 1000 LB		0.03		
Years of life lost		1,295	94065	30210052

LB = live births \* Severe disability is defined as: wheelchair dependence, needing help with transfers, continence care and daily living, mostly low IQ, kyphosis, pressure sores, epilepsy and visual defects (a few blind) (Oakeshott and Hunt 2003)

**Norway****Neural Tube Defects****NTD Epidemiology 2.1: Data on affected pregnancies: Research studies**

Study author, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies listed above (or in section NTD-E2.1 of the Tool), enter the best estimates for the prevalence of affected births and terminations in the country, and a range of values to reflect uncertainty or within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	LB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of affected stillbirths	SB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of terminations of pregnancy due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

TB = total births (live births + stillbirths); ToP = termination of pregnancy



**Norway****Neural Tube Defects****NTD Epidemiology 2.2: Data on affected pregnancies: Surveillance**

Based on surveillance data, enter the best estimates for the prevalence of the condition in live births, stillbirths and pregnancy terminations in the country. Give a range of values to reflect uncertainty and within-country variation, and use comments for information on data quality, uncertainty and representativeness.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	Birth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Estimates for the total country/territory	Number of affected stillbirths	Stillbirth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Estimates for the total country/territory	Number of ToP due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

TB = total births (live births + stillbirths); ToP = termination of pregnancy

## Norway

## Neural Tube Defects

## NTD Epidemiology 2.3: Data on affected pregnancies: Other sources

	Source 1:	Source 2:	Notes
Enter year and source of data – use last year with information available.			
<b>Basic Numbers</b>			
Number of affected live births / year, from data source			
Total number of live births / year, from data source			
Number of affected still births / year, from data source			
Total number of stillbirths / year, from data source			
Number of ToP for affected fetus / year from data source			
Total number of affected births / year (live and still)	0	0	
Total number of births / year, from data source	0	0	
Total number of ToP / year, from data source			
Total number of women aged 15-44			
<b>Live birth prevalence: recorded and estimated</b>			
Recorded live birth prevalence (affected recorded live births / 1000 recorded total births)	#DIV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected live births in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded live births (number of recorded live births / total live births in country or territory)			Range: 0 to 1
Estimated live birth prevalence (recorded prevalence / completeness)	#DIV/0!	#DIV/0!	
Estimated true number of affected live births in data source (number of recorded affected live births / completeness)	#DIV/0!	#DIV/0!	
Estimated number of affected live births in total population (number of affected live births from data source / (coverage x completeness))	#DIV/0!	#DIV/0!	
<b>Stillbirth prevalence: recorded and estimated</b>			
Recorded stillbirth prevalence (affected recorded still births / 1000 recorded total births)	#DIV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected stillbirths in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded stillbirths (number of recorded still births / total still births in country or territory)			Range: 0 to 1
Estimated stillbirth prevalence (recorded prevalence / completeness)	#DIV/0!	#DIV/0!	
Estimated true number of affected stillbirths in data source (number of recorded affected still births / completeness)	#DIV/0!	#DIV/0!	

Estimated number of affected stillbirths in total population (number of affected still births from data source / (coverage x completeness))	#DIV/0!	#DIV/0!
---------------------------------------------------------------------------------------------------------------------------------------------	---------	---------

ToP prevalence: recorded and estimated			
Recorded ToP prevalence (ToP in affected fetuses / 1000 women aged 15-44)	#DIV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected pregnancy terminations in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded ToP (number of recorded ToP / total ToP in country or territory)			Range: 0 to 1
Estimated ToP prevalence (recorded prevalence / estimated completeness)	#DIV/0!	#DIV/0!	
Estimated true number of ToP in data source (number of recorded ToP / completeness)	#DIV/0!	#DIV/0!	
Estimated number of ToP in total population (number of ToP from data source / (coverage x completeness))	#DIV/0!	#DIV/0!	

**Based on the sources above**, enter the best prevalence estimates for your population, and a range of values to reflect uncertainty of estimates and within country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the whole country/territory	Number of affected live births	LB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of affected still births	SB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of ToP due to condition	ToP /1000 TB
Best estimate		
Lower estimate		
Higher estimate		

TB = total births (live births + stillbirths); ToP = termination of pregnancy

## Norway

## Neural Tube Defects

## NTD Epidemiology 2.4: Summary of affected pregnancies

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Number of annual affected <b>live births</b>			12			
Annual birth prevalence / 1000 TB			0.23			
Number of annual affected <b>still births</b>			1			
Stillbirth prevalence / 1000 TB/year			0.02			
Number of <b>terminations of pregnancy</b> in affected fetuses /year			45			
Affected ToP / 1000 TB			0.81			

If there are specific sub-types of condition, you can repeat this exercise below. However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

TB = total births (live births + stillbirths); ToP = termination of pregnancy

**Norway****Neural Tube Defects****NTD Epidemiology 2.5: Sub-population variation in affected pregnancies**

If the birth prevalence rates vary by population sub-group (e.g. geographically or by another factor), indicate any population groups with different prevalence estimates from the whole population and describe reasons for variation. If a group is substantially different from the general population, you may wish to conduct a needs assessment for that group alone.

Population sub-group	Number of affected live births	LB prevalence / 1000 TB	Reason for variation

Population sub-group	Number of affected stillbirths	SB prevalence / 1000 TB	Reason for variation

Population sub-group	Number of ToP in affected pregnancies	ToP prevalence / 1000 TB	Reason for variation

TB = total births (live births + stillbirths); ToP = termination of pregnancy

**Norway****Neural Tube Defects****NTD Epidemiology 3.1: Mortality data: Research studies**

Source, year, site	Sample size	Age group	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for the specific mortality by age-group e.g. infant, under-5s, etc., as appropriate, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Mortality estimates	Number of deaths	Ratio (deaths / 1000 LB)	Comments
<b>Neonatal group (&lt;28 days)</b>			
Best estimate			
Lower estimate			
Higher estimate			
<b>Infant group (&lt;1 year)</b>			
Best estimate			
Lower estimate			
Higher estimate			
<b>Under-5 group (&lt;5 years)</b>			
Best estimate			
Lower estimate			
Higher estimate			
<b>Other age group:</b>			
Best estimate			
Lower estimate			
Higher estimate			

LB = live births

## Norway

## Neural Tube Defects

## NTD Epidemiology 3.2: Mortality data: Vital registration data

Fill in the blank cells based on your vital registration data.	
Enter year and source of data	
<b>Registered data</b>	
Total registered live births	
Registered condition-specific neonatal deaths (first 28 days of life)	
Registered condition-specific infant deaths (first year of life)	
Registered condition-specific under-5 deaths (first 5 years of life)	
Registered condition-specific neonatal mortality ratio (condition-specific neonatal deaths / 1000 live births in the same year)	#DIV/0!
Registered condition-specific infant mortality (condition-specific infant deaths / 1000 live births in the same year)	#DIV/0!
Registered condition-specific under-5 mortality (condition-specific under-5 deaths / 1000 live births in the same year)	#DIV/0!

**Adjustment for under-ascertainment of cause of death and sub-registration of deaths:** Enter estimates in the highlighted cells. It is not always possible to adjust the estimates, in which case you may give the value '1', accepting that the estimates in these cases will usually be biased towards low values. (Or you may move to the next section.)  
It is assumed that under-ascertainment is stable across age-groups; if ascertainment varies by age-group, you could use separate estimates for each age group.

Estimated completeness of recording: what proportion of deaths in affected persons were registered as such?		Range: 0 to 1
Population coverage: what proportion of the total country/territory population is covered by the vital registration?		Range: 0 to 1
Death ascertainment (population coverage x completeness)	0	
<b>Estimated values for the total country/ territory population</b>		
Estimated number of live births in total population	#DIV/0!	
Estimated number of neonatal deaths in total population (number of deaths registered in neonatal period / ascertainment)	#DIV/0!	
Estimated number of infant deaths in total population (number of deaths registered in first year of life / ascertainment)	#DIV/0!	
Estimated number of under-5 deaths in total population (number of deaths registered in under-5s / ascertainment)	#DIV/0!	
Estimated neonatal mortality ratio (estimated neonatal deaths / 1000 live births)	#DIV/0!	
Estimated infant mortality ratio (estimated infant deaths / 1000 live births)	#DIV/0!	
Estimated under-5 mortality ratio (estimated under-5 deaths / 1000 live births)	#DIV/0!	



**Norway****Neural Tube Defects****NTD Epidemiology 3.3: Mortality data: Other sources**

Source, year, site	Sample size	Age group	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Neonatal mortality		Infant mortality		Under-5 mortality	
Estimates for the total country/territory	Value	Ratio/1000 LB	Value	Ratio/1000 LB	Value	Ratio/1000 LB
Best estimate						
Lower estimate						
Higher estimate						

**Norway****Neural Tube Defects****NTD Epidemiology 3.4: Summary mortality estimates**

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of data collection						
Number of annual deaths in affected persons			11			
Number of annual live births (in 1000s)			55			
Number of annual affected neonatal deaths			1			
Number of affected neonatal deaths / 1000 LB			0.01			
Number of annual affected infant deaths			1			
Number of affected infant deaths / 1000 LB			0.03			
Number of annual affected under-5 deaths			2			
Number of affected under-5 deaths / 1000 LB			0.03			
Mean life expectancy at birth in affected people			56.0			
Other indicators (e.g. survival following surgical procedure, etc)						

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

## Norway

## Neural Tube Defects

## NTD Epidemiology 3.5: Sub-population variation in mortality

Age group: neonatal Population sub-group	Number of deaths in affected persons	Cause-specific, group-specific neonatal mortality ratio / 1000 LB	Reason for variation

Age group: infant Population sub-group	Number of deaths in affected persons	Cause-specific, group-specific infant mortality ratio / 1000 LB	Reason for variation

Age group: under 5 Population sub-group	Number of deaths in affected persons	Cause-specific, group-specific under-5 mortality ratio / 1000 LB	Reason for variation

Age group: ..... Population sub-group	Number of deaths in affected persons	Cause-specific, group-specific mortality ratio / 1000 population	Reason for variation

**Norway****Neural Tube Defects****NTD Epidemiology 4.1: Population prevalence: Research studies**

Study, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for population prevalence, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

**Norway****Neural Tube Defects****NTD Epidemiology 4.2: Population prevalence: Other sources**

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

**Norway****Neural Tube Defects****NTD Epidemiology 4.3: Summary of population prevalence**

Source of estimates	Estimated total population number of affected persons	Range	Estimated total population prevalence / 1000 persons	Range
1				
2				
3				
4				
5				
PHGDB				
<b>Chosen estimates</b>				

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

**Norway****Neural Tube Defects****NTD Epidemiology 4.4: Sub-population prevalence variation**

Population sub-group	Number of affected people	Total number of people in population sub-group	Population prevalence per 1000 people	Reason for variation
			#DIV/0!	
			#DIV/0!	
			#DIV/0!	
			#DIV/0!	

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Formula in column D: Number of affected people/ (Total number of people in population subgroup/1000)

**Norway****Neural Tube Defects****NTD Interventions 1: Effect of folic acid fortification**

This sheet allows you to estimate the potential reduction in NTD prevalence through fortification of food with folic acid. Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coverage. Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation		Notes
Present estimated NTD prevalence per 1000 TB		
Present dosage (ppm)		Range: 1.5 to 3
Present coverage of fortification		Range: 0 to 1
Baseline NTD prevalence per 1000 TB, with no folic acid fortification*		
Minimum prevalence NTD / 1000 births	0.9	This value is fixed at 0.9

Potential scenarios, based on your present situation		
Vary dosage (ppm)		Range: 1.5 to 3
Vary proportional population coverage		Range: 0 to 1
Estimated NTD prevalence with this scenario, per 1000 TB		<- Do not modify this cell!
Absolute prevalence reduction with this scenario, per 1000 TB		<- Do not modify this cell!

ppm = parts per million

TB = total births (live births + stillbirths)

\* Not considering the effects of other interventions on prevalence.

**Formula in B13:** IF(B10="";"", IF(((B10-(1.07\*B12)+(0.15\*B11\*B12))/(1-0.88\*B12))<B15;B15;((B10-(1.07\*B12)+(0.15\*B11\*B12))/(1-0.88\*B12))))

**Formula in B20:** IF(B13="";"", IF(B13=0.9;0.9; IF((1.07\*B19+0.12\*B13\*B19-0.15\*(IF(B18="";B11;B18))\*B19+B13-B13\*B19)<B15;B15;(1.07\*B19+0.12\*B13\*B19-0.15\*(IF(B18="";B11;B18))\*B19+B13-B13\*B19))))

**Formula in B21:** IF(B20="";"", B13-B20)

See sheet NTD-Appx for explanation of regression.



**Norway****Neural Tube Defects****NTD Interventions 2: Effect of folic acid supplementation**

This sheet allows you to estimate the potential reduction in NTD incidence through folic acid supplementation for pregnant women.

Please enter a value for population coverage of folic acid supplementation, to determine its potential effect.

<b>Effect of supplementation (with no fortification)</b>		Notes
Baseline prevalence with no folic acid intervention (per 1000 TB)		This can be taken from the appropriate cell (baseline NTD prevalence) in sheet NTD-Interv1.
Maximum proportional reduction (assuming 100% coverage)	0.72	This value is fixed at 0.72
Population supplementation coverage		Range: 0 to 1
Actual proportional reduction	0	Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000	Baseline incidence x Actual proportional reduction
Minimum prevalence	0.9	This value is fixed at 0.9
New prevalence	0.000	Baseline prevalence-((Maximum proportional reduction X Population supplementation coverage) x Baseline prevalence)
% prevalence reduction	#DIV/0!	1 – (New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000	Baseline prevalence- New prevalence
<b>Final prevalence following supplementation</b>	<b>0.900</b>	Cannot go below 0.9 / 1000 LB

Now you can see below the potential combined effect of folate fortification and supplementation:

<b>Additional effect of supplementation, given fortification</b>		This value can be changed.
	<b>New prevalence</b>	
After fortification		This value set in sheet NTD-Interv1
After supplementation		
After fortification and supplementation	0.000	Requires input in blank cells above <sup>1</sup>
<b>% reduction</b>	<b>#DIV/0!</b>	Requires input in blank cells above <sup>2</sup>
<b>Final prevalence after fortification and supplementation</b>		

TB = total births (live births + stillbirths)

<sup>1</sup>New Prevalence after fortification-(Additional effect of supplementation x Final prev. following supplemen.)

<sup>2</sup>If New prevalence after fortification < minimum prevalence then use (Baseline prev – min prevalence)/baseline prevalence)

Otherwise use: (Baseline prevalence – new prevalence after fortification and supplementation)/baseline prevalence

**Norway****Neural Tube Defects****NTD Interventions 3: Effect of prenatal screening and pregnancy termination**

Assumption: prenatal services are equally used for cases which would lead to still births and live births.

This could overestimate the impact of ToP if in fact ToP is more likely for severe cases that would result in stillbirth.

Conversely, the impact of ToP could be underestimated if screening is only available to high-income women at lower risk.

100% specificity of prenatal diagnosis assumed.

Baseline prevalence, per 1000 TB (LB + SB)		See previous two sheets. Use baseline either before or after folic acid interventions.
<b>Variables</b>		
Coverage of prenatal screening		Range: 0 to 1
Proportion of screen-positive cases receiving diagnosis		Range: 0 to 1
Proportion of diagnosed cases ending in pregnancy termination		Range: 0 to 1
<b>Results</b>		
% prevalence reduction due to PND & pregnancy termination <sup>1</sup>		0%
Prevalence reduction due to PND & pregnancy termination, per 1000 TB <sup>2</sup>		0.000
Final birth prevalence of NTDs after PND & pregnancy termination, per 1000 TB <sup>3</sup>		0.000

PNS = prenatal screening

ToP = termination of pregnancy

TB = total births (live births + still births)

<sup>1</sup>Coverage of screening X Proportion of screen-positive cases receiving diagnosis x Proportion of cases ending in pregnancy termination

<sup>2</sup>% prevalence reduction due to PND and termination x Baseline prevalence

<sup>3</sup>Baseline prevalence – Prevalence reduction due to PND & termination

**Norway****Neural Tube Defects****NTD Interventions 4: Combined effects of folic acid interventions and prenatal screening**

This sheet will only work if the previous three sheets (NTD-Interv1, 2 3) have been completed.

Variables		Notes
Baseline prevalence (per 1000 TB)		See e.g. Baseline prior to FA interventions in sheet NTD-Interv1
Prevalence reduction through FA interventions (per 1000 TB)	0.000	Set in sheet NTD-Interv2
% prevalence reduction after folic acid <sup>1</sup>	#VALUE!	
Coverage of prenatal diagnosis	0	Set in sheet NTD-Interv3
Prevalence of pregnancy termination in confirmed cases	0	Set in sheet NTD-Interv3
Prevalence reduction through PNS	0.000	Set in sheet NTD-Interv3
% prevalence reduction due to PNS <sup>2</sup>	0%	
<b>Final prevalence after folic acid and PNS (per 1000 TB)<sup>3</sup></b>	<b>0.000</b>	
Combined prevalence reduction (per 1000 TB) <sup>4</sup>	0.000	
Combined % prevalence reduction <sup>5</sup>	#VALUE!	

PNS = prenatal screening

TB = total births (live births + stillbirths)

FA = folic acid

<sup>1</sup>Prevalence reduction through FA interventions/Baseline prevalence

<sup>2</sup>Coverage of prenatal diagnosis x Prevalence of pregnancy termination of confirmed cases

<sup>3</sup>Baseline prevalence = Prevalence reduction through FA interventions – Prevalence reduction through PNS

<sup>4</sup>Baseline prevalence – Final prevalence after folic acid and PNS

<sup>5</sup>1- (Final prevalence after folic acid and PNS/Baseline prevalence)

**Norway****Neural Tube Defects****NTD Needs Assessment Calculator 1: Quantitative baseline****Table NTD-NA1a Burden of Neural Tube Defects in pregnancy, at birth and at population level**

Indicator	Chosen estimates			Notes
	Number (n)	n/1000 TB	Range of prevalence (/1000 TB)	
Annual affected live births (LB)	0	0	0	Drawn from sheet E2.4
Annual affected stillbirths (SB)	0	0	0	Drawn from sheet E2.4
Annual affected births (LB+SB)	0	0		Drawn from sheet E2.4
Annual affected persons (all age groups)	0	0	0	Drawn from sheet E1.1

**Table NTD-NA1b Neural Tube Defects mortality indicators**

Indicator	Chosen estimates			Notes
	Number (n)	n/1000 LB	Range of prevalence (/1000 TB)	
Annual overall mortality	0			Drawn from sheet E3.4
Annual neonatal mortality	0	0	0	Drawn from sheet E3.4
Annual infant mortality	0	0	0	Drawn from sheet E3.4
Annual under-5 mortality	0	0	0	Drawn from sheet E3.4
Mean life expectancy at birth among affected people	0		0	Drawn from sheet E3.4

TB = total births (live births + stillbirths)

**Norway****Neural Tube Defects****NTD Needs Assessment Calculator 3: Quantitative assessment of interventions**

<b>Table NTD-NA3a</b>	<b>Estimated prevalence in the absence of interventions for Neural Tube Defects</b>	
Indicator	Number (n)	Prevalence (n/1000)
Potential live births		
Potential still births		

<b>Table NTD-NA3b</b>	<b>Current situation in relation to interventions before birth</b>		
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB
Effect of family planning, education			
Effect of folic acid fortification			
Effect of folic acid supplementation			
Effect of prenatal diagnosis			
Overall effect			

<b>Table NTD-NA3c</b>	<b>Target situation in relation to interventions before birth</b>		
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB
Effect of family planning, education			
Effect of folic acid fortification			
Effect of folic acid supplementation			
Effect of prenatal diagnosis			
Overall effect			

<b>Table NTD-NA3d</b>	<b>Current situation in relation to interventions after birth</b>		
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 TB
Effect of newborn diagnosis			
Effect of surgical treatment			
Effect of social care and support			
Effect of rehabilitation			
Overall effect			

Table NTD-NA3e	Target situation in relation to interventions after birth		
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 TB
Effect of newborn diagnosis			
Effect of surgical treatment			
Effect of social care and support			
Effect of rehabilitation			
Overall effect			

Table NTD-NA3f	Current and desired outcomes			
	Current situation		Target situation	
Indicator	Annual number (n)	Prevalence (n/1000)	Annual number (n)	Prevalence (n/1000)
<b>Estimated affected pregnancies</b>				
Live births (LB)	0	0		
Stillbirths (SB)	0	0		
Total births (LB+SB)	0	0		
<b>Estimated population prevalence</b>				
All age groups				
<b>Estimated mortality / 1000 live births</b>				
Neonatal deaths	0	0		
Infant deaths	0	0		
Under-5 deaths	0	0		

TB = total births (live births + stillbirths)

**Norway****Neural Tube Defects****NTD Needs assessment appendix: Regression estimating effect of folic acid fortification**

Data from Wald et al.<sup>1</sup> was used to create a regression. The following output, adapted from Stata, gives the basis for the formula used in cell B13 of sheet NTD-Interv1.

Due to the use of a limited data set, the regression is accurate within a limited range.

Command
---------

```
regress incid baseline ppm
```

Output
--------

Source	SS	df	MS	Number of obs = 12
Model	0.282	2	0.141	Prob > F = 0.0164
Residual	0.188	9	0.021	R-squared = 0.5991
				Adj R-squared = 0.5100
Total	0.470	11	0.043	Root MSE = .14468

incid	Coef.	Std. Err.	t	P> t	95% Conf. Interval
baseline	<b>0.121</b>	0.071	1.69	0.12	-0.041 0.283
ppm	<b>-0.154</b>	0.047	3.25	0.010	-0.261 -0.047
_cons	<b>1.072</b>	0.164	6.52	0.000	0.700 1.444

Prevalence = (0.12 x baseline prevalence) – (0.15 x ppm) + 1.07

<sup>1</sup>Wald NJ, Law MR, Morris JK, Wald DS. 2001. Quantifying the effect of folic acid. Lancet 358:2069-73.